Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VIAL HEALTH TECHNOLOGY, INC. via VIAL HEALTH TECHNOLOGY, INC.
2026 · first_quarter · 1T
Regulatory and policy issues related to drug development and clinical trials
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Vice President of the U.S., White House Office
VIAL HEALTH TECHNOLOGY, INC. via VIAL HEALTH TECHNOLOGY, INC.
2025 · fourth_quarter · Q4
Source: Senate LDA
Regulatory and policy issues related to drug development and clinical trials
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Vice President of the U.S., White House Office
VIAL HEALTH TECHNOLOGY, INC. via VIAL HEALTH TECHNOLOGY, INC.
2025 · third_quarter · Q3
Regulatory and policy issues related to drug development and clinical trials
Filing targets: Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, Vice President of the U.S., White House Office
VIAL HEALTH TECHNOLOGY, INC. via VIAL HEALTH TECHNOLOGY, INC.
2025 · third_quarter · RR
Advocated and educated policymakers on issues related to clinical trials and drug development.